We found that intravenously administered CCR2+HSCs migrate preferentially to the CNS tumor microenvironment, differentiate into CD11c+ APCs at the tumor site, and reprogram gene expression within the immunosuppressive tumor microenvironment, while targeting multiple suppressive pathways at once. The gene discussed is CCR2; the disease is neoplasm.